

Marc P Bonaca

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7114055/publications.pdf>

Version: 2024-02-01

207
papers

19,613
citations

31902

53
h-index

11581

135
g-index

240
all docs

240
docs citations

240
times ranked

16734
citing authors

#	ARTICLE	IF	CITATIONS
1	Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2019, 380, 347-357.	13.9	4,159
2	SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. <i>Lancet</i> , The, 2019, 393, 31-39.	6.3	1,958
3	Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. <i>New England Journal of Medicine</i> , 2015, 372, 1791-1800.	13.9	1,585
4	Vorapaxar in the Secondary Prevention of Atherothrombotic Events. <i>New England Journal of Medicine</i> , 2012, 366, 1404-1413.	13.9	841
5	Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. <i>Lancet Oncology</i> , The, 2018, 19, 1579-1589.	5.1	742
6	Rivaroxaban in Peripheral Artery Disease after Revascularization. <i>New England Journal of Medicine</i> , 2020, 382, 1994-2004.	13.9	566
7	Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease. <i>Circulation</i> , 2018, 137, 338-350.	1.6	559
8	Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. <i>Circulation</i> , 2019, 139, 2022-2031.	1.6	523
9	Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. <i>Circulation</i> , 2019, 139, 2528-2536.	1.6	415
10	Effect of Darapladib on Major Coronary Events After an Acute Coronary Syndrome. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 1006.	3.8	375
11	Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2719-2728.	1.2	303
12	Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. <i>European Heart Journal</i> , 2016, 37, ehv443.	1.0	293
13	Myocarditis in the Setting of Cancer Therapeutics. <i>Circulation</i> , 2019, 140, 80-91.	1.6	278
14	Vorapaxar in Patients With Peripheral Artery Disease. <i>Circulation</i> , 2013, 127, 1522-1529.	1.6	261
15	Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus. <i>Circulation</i> , 2020, 141, 1227-1234.	1.6	241
16	Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction. <i>Circulation</i> , 2019, 139, 2516-2527.	1.6	224
17	Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients. <i>New England Journal of Medicine</i> , 2018, 379, 1107-1117.	13.9	205
18	Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2 ^Â P-TIMI 50 trial. <i>Lancet</i> , The, 2012, 380, 1317-1324.	6.3	202

#	ARTICLE	IF	CITATIONS
19	Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1591.	3.8	190
20	Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS-TIMI 54. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2732-2740.	1.2	179
21	Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: Design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 ^{Â°} P)-TIMI 50 trial. <i>American Heart Journal</i> , 2009, 158, 335-341.e3.	1.2	166
22	Acute Limb Ischemia and Outcomes With Vorapaxar in Patients With Peripheral Artery Disease. <i>Circulation</i> , 2016, 133, 997-1005.	1.6	163
23	Effect of the Novel Thienopyridine Prasugrel Compared With Clopidogrel on Spontaneous and Procedural Myocardial Infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Trombolysis in Myocardial Infarction 38. <i>Circulation</i> , 2009, 119, 2758-2764.	1.6	155
24	American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation Universal Definition of Myocardial Infarction Classification System and the Risk of Cardiovascular Death. <i>Circulation</i> , 2012, 125, 577-583.	1.6	153
25	Atherothrombotic Risk Stratification and the Efficacy and Safety of Vorapaxar in Patients With Stable Ischemic Heart Disease and Previous Myocardial Infarction. <i>Circulation</i> , 2016, 134, 304-313.	1.6	143
26	Role of ST2 in Non-ST-Elevation Acute Coronary Syndrome in the MERLIN-TIMI 36 Trial. <i>Clinical Chemistry</i> , 2012, 58, 257-266.	1.5	140
27	Growth Differentiation Factor-15 and Risk of Recurrent Events in Patients Stabilized After Acute Coronary Syndrome. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011, 31, 203-210.	1.1	138
28	Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y ₁₂ inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54. <i>European Heart Journal</i> , 2016, 37, 1133-1142.	1.0	138
29	Prospective Evaluation of the Prognostic Implications of Improved Assay Performance With a Sensitive Assay for Cardiac Troponin I. <i>Journal of the American College of Cardiology</i> , 2010, 55, 2118-2124.	1.2	120
30	The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial. <i>American Heart Journal</i> , 2018, 200, 83-89.	1.2	117
31	Microvascular Disease, Peripheral Artery Disease, and Amputation. <i>Circulation</i> , 2019, 140, 449-458.	1.6	114
32	Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 899-911.	5.5	111
33	Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1145-1154.	1.2	108
34	Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD). <i>American Heart Journal</i> , 2018, 199, 83-91.	1.2	104
35	DECLARE-TIMI 58: Participants' baseline characteristics. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1102-1110.	2.2	96
36	Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 934-943.	5.5	96

#	ARTICLE	IF	CITATIONS
37	Efficacy and Safety of Vorapaxar in Patients With Prior Ischemic Stroke. <i>Stroke</i> , 2013, 44, 691-698.	1.0	89
38	Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin—Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial. <i>American Heart Journal</i> , 2014, 167, 437-444.e5.	1.2	89
39	Long-term Tolerability of Ticagrelor for the Secondary Prevention of Major Adverse Cardiovascular Events. <i>JAMA Cardiology</i> , 2016, 1, 425.	3.0	88
40	Pharmacological Treatment and Current Management of Peripheral Artery Disease. <i>Circulation Research</i> , 2015, 116, 1579-1598.	2.0	87
41	Prognostic Performance of Multiple Biomarkers in Patients With Non—ST-Segment Elevation Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1644-1653.	1.2	86
42	Cardiac mortality in patients randomised to elective coronary revascularisation plus medical therapy or medical therapy alone: a systematic review and meta-analysis. <i>European Heart Journal</i> , 2021, 42, 4638-4651.	1.0	80
43	Prognostic Performance of a High-Sensitivity Cardiac Troponin I Assay in Patients with Non—ST-Elevation Acute Coronary Syndrome. <i>Clinical Chemistry</i> , 2014, 60, 158-164.	1.5	74
44	Efficacy and Safety of Ticagrelor Over Time in Patients With Prior MI in PEGASUS-TIMI 54. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1368-1375.	1.2	74
45	Vorapaxar in Patients With Diabetes Mellitus and Previous Myocardial Infarction. <i>Circulation</i> , 2015, 131, 1047-1053.	1.6	73
46	Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial. <i>European Heart Journal</i> , 2016, 37, ehv482.	1.0	70
47	Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial. <i>Lancet</i> , The, 2018, 392, 2269-2279.	6.3	70
48	Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States. <i>Journal of the American Heart Association</i> , 2015, 4, e001505.	1.6	62
49	Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. <i>New England Journal of Medicine</i> , 2015, 373, 1271-1275.	13.9	62
50	The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism. <i>Circulation</i> , 2020, 141, 1600-1607.	1.6	61
51	Recurrent Aortic Dissection. <i>Circulation</i> , 2016, 134, 1013-1024.	1.6	58
52	Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization. <i>Circulation</i> , 2020, 142, 2219-2230.	1.6	58
53	Central obesity and cardiovascular outcomes in patients with acute coronary syndrome: observations from the MERLIN-TIMI 36 trial. <i>Heart</i> , 2011, 97, 1782-1787.	1.2	56
54	Comparative Efficacy of Endovascular Revascularization Versus Supervised Exercise Training in Patients With Intermittent Claudication. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 712-724.	1.1	56

#	ARTICLE	IF	CITATIONS
55	Ticagrelor for Secondary Prevention of Atherothrombotic Events in Patients With Multivessel Coronary Disease. <i>Journal of the American College of Cardiology</i> , 2018, 71, 489-496.	1.2	56
56	Prospective Evaluation of Pregnancy-Associated Plasma Protein-A and Outcomes in Patients With Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2012, 60, 332-338.	1.2	55
57	Antithrombotics in Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2009, 54, 969-984.	1.2	53
58	Contemporary Medical Management of Peripheral Artery Disease. <i>Circulation Research</i> , 2021, 128, 1868-1884.	2.0	53
59	Randomized Controlled Trial of Social Media: Effect of Increased Intensity of the Intervention. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	52
60	Potent P2Y ₁₂ Inhibitors in Men Versus Women. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1549-1559.	1.2	51
61	Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58. <i>Circulation</i> , 2020, 142, 734-747.	1.6	44
62	Coronary Stent Thrombosis With Vorapaxar Versus Placebo. <i>Journal of the American College of Cardiology</i> , 2014, 64, 2309-2317.	1.2	41
63	Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction. <i>Circulation</i> , 2016, 134, 861-871.	1.6	40
64	Efficacy and Safety of Vorapaxar With and Without a Thienopyridine for Secondary Prevention in Patients With Previous Myocardial Infarction and No History of Stroke or Transient Ischemic Attack. <i>Circulation</i> , 2015, 132, 1871-1879.	1.6	39
65	Peripheral Revascularization in Patients With Peripheral Artery Disease With Vorapaxar. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 2157-2164.	1.1	39
66	Diagnosis and Management of Acute Aortic Syndromes: Dissection, Intramural Hematoma, and Penetrating Aortic Ulcer. <i>Current Cardiology Reports</i> , 2014, 16, 536.	1.3	38
67	New cardiovascular prevention guidelines: How to optimally manage dyslipidaemia and cardiovascular risk in 2021 in patients needing secondary prevention?. <i>Atherosclerosis</i> , 2021, 319, 51-61.	0.4	37
68	Society for Vascular Surgery appropriate use criteria for management of intermittent claudication. <i>Journal of Vascular Surgery</i> , 2022, 76, 3-22.e1.	0.6	37
69	Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study. <i>American Heart Journal</i> , 2021, 235, 12-23.	1.2	36
70	Osteoprotegerin and cardiovascular mortality in patients with non-ST elevation acute coronary syndromes. <i>Heart</i> , 2012, 98, 786-791.	1.2	34
71	Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 1929-1938.	0.8	33
72	Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial. <i>Circulation</i> , 2019, 139, 366-375.	1.6	32

#	ARTICLE	IF	CITATIONS
73	Gut Microbiota-Dependent Trimethylamine N-oxide and Cardiovascular Outcomes in Patients With Prior Myocardial Infarction: A Nested Case Control Study From the PEGASUS-TIMI 54 Trial. <i>Journal of the American Heart Association</i> , 2020, 9, e015331.	1.6	32
74	Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic Disease. <i>Circulation</i> , 2021, 143, 470-478.	1.6	32
75	Supervised Exercise Therapy for Symptomatic Peripheral Artery Disease Among Medicare Beneficiaries Between 2017 and 2018: Participation Rates and Outcomes. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e007953.	0.9	31
76	New Ischemic Stroke and Outcomes With Vorapaxar Versus Placebo. <i>Journal of the American College of Cardiology</i> , 2014, 64, 2318-2326.	1.2	30
77	Total Ischemic Event Reduction With Rivaroxaban After Peripheral Arterial Revascularization in the VOYAGER PAD Trial. <i>Journal of the American College of Cardiology</i> , 2021, 78, 317-326.	1.2	30
78	Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54. <i>European Heart Journal</i> , 2020, 41, 1625-1632.	1.0	27
79	Clinical Application of High-Sensitivity Troponin Testing in the Atherosclerotic Cardiovascular Disease Framework of the Current Cholesterol Guidelines. <i>JAMA Cardiology</i> , 2020, 5, 1255.	3.0	27
80	Real-World Application of Δ -Troponin. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1239-1241.	1.2	26
81	Baseline adiponectin concentration and clinical outcomes among patients with diabetes and recent acute coronary syndrome in the EXAMINE trial. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 962-969.	2.2	26
82	Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE-TIMI 58 study. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1357-1368.	2.2	26
83	Evaluation of the diagnostic performance of current and next-generation assays for cardiac troponin I in the BWH-TIMI ED Chest Pain Study. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2013, 2, 195-202.	0.4	25
84	Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 200-206.	1.4	25
85	Prevalence and Outcomes of Polyvascular (Coronary, Peripheral, or Cerebrovascular) Disease in Patients With Diabetes Mellitus (From the SAVOR-TIMI 53 Trial). <i>American Journal of Cardiology</i> , 2019, 123, 145-152.	0.7	25
86	Nonculprit Lesion Myocardial Infarction Following Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1095-1106.	1.2	25
87	Effect of Rivaroxaban and Aspirin in Patients With Peripheral Artery Disease Undergoing Surgical Revascularization: Insights From the VOYAGER PAD Trial. <i>Circulation</i> , 2021, 144, 1104-1116.	1.6	25
88	Studying the coagulopathy of COVID-19. <i>Lancet, The</i> , 2022, 399, 118-119.	6.3	25
89	External validation of the TIMI risk score for secondary cardiovascular events among patients with recent myocardial infarction. <i>Atherosclerosis</i> , 2018, 272, 80-86.	0.4	24
90	Effect of vorapaxar on cardiovascular and limb outcomes in patients with peripheral artery disease with and without coronary artery disease: Analysis from the TRA 2 ^Â P-TIMI 50 trial. <i>Vascular Medicine</i> , 2020, 25, 124-132.	0.8	24

#	ARTICLE	IF	CITATIONS
91	Defining a Role for Novel Biomarkers in Acute Coronary Syndromes. <i>Clinical Chemistry</i> , 2008, 54, 1424-1431.	1.5	23
92	Cost-Effectiveness of Long-Term Ticagrelor in Patients With Prior Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2017, 70, 527-538.	1.2	23
93	Effectiveness of Blood Lipid Management in Patients With Peripheral Artery Disease. <i>Journal of the American College of Cardiology</i> , 2021, 77, 3016-3027.	1.2	23
94	Effect of evolocumab on acute arterial events across all vascular territories : results from the FOURIER trial. <i>European Heart Journal</i> , 2021, 42, 4821-4829.	1.0	23
95	Frequency, Predictors, and Impact of Combined Antiplatelet Therapy on Venous Thromboembolism in Patients With Symptomatic Atherosclerosis. <i>Circulation</i> , 2018, 137, 684-692.	1.6	22
96	Sex, Permanent Drug Discontinuation, and Study Retention in Clinical Trials. <i>Circulation</i> , 2021, 143, 685-695.	1.6	22
97	Consistent platelet inhibition with ticagrelor 60 mg twice-daily following myocardial infarction regardless of diabetes status. <i>Thrombosis and Haemostasis</i> , 2017, 117, 940-947.	1.8	21
98	High-Sensitivity Troponin I in Stable Patients with Atherosclerotic Disease in the TRA 2 ^Â P - TIMI 50 Trial. <i>Clinical Chemistry</i> , 2017, 63, 307-315.	1.5	19
99	Reduction in Acute Limb Ischemia With Rivaroxaban Versus Placebo in Peripheral Artery Disease After Lower Extremity Revascularization: Insights From VOYAGER PAD. <i>Circulation</i> , 2021, 144, 1831-1841.	1.6	19
100	Safety and Effectiveness of Paclitaxel Drug-Coated Devices in Peripheral Artery Revascularization. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1768-1778.	1.2	19
101	Evaluation of the diagnostic performance of heart-type fatty acid binding protein in the BWH-TIMI ED chest pain study. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 36, 361-367.	1.0	18
102	Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials. <i>European Journal of Preventive Cardiology</i> , 2022, 29, e181-e189.	0.8	18
103	Prognostic performance of a high-sensitivity assay for cardiac troponin I after non-ST elevation acute coronary syndrome: Analysis from MERLIN-TIMI 36. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2015, 4, 431-440.	0.4	17
104	International Validation of the Thrombolysis in Myocardial Infarction (TIMI) Risk Score for Secondary Prevention in Post-AMI Patients: A Collaborative Analysis of the Chronic Kidney Disease Prognosis Consortium and the Risk Validation Scientific Committee. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	17
105	Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long-Term Ticagrelor in Stable Patients With Prior Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2021, 10, e017008.	1.6	17
106	SCH 530348: a novel oral thrombin receptor antagonist. <i>Future Cardiology</i> , 2009, 5, 435-442.	0.5	16
107	Diagnostic evaluation of the MRP-8/14 for the emergency assessment of chest pain. <i>Journal of Thrombosis and Thrombolysis</i> , 2012, 34, 229-234.	1.0	16
108	Clinical Features, Use of Evidence-Based Therapies, and Cardiovascular Outcomes Among Patients With Chronic Kidney Disease Following Non-ST-Elevation Acute Coronary Syndrome. <i>Clinical Cardiology</i> , 2014, 37, 350-356.	0.7	16

#	ARTICLE	IF	CITATIONS
109	Pharmacokinetic-pharmacodynamic modelling of platelet response to ticagrelor in stable coronary artery disease and prior myocardial infarction patients. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 413-421.	1.1	16
110	Prognostic Implications of Low Level Cardiac Troponin Elevation Using High-Sensitivity Cardiac Troponin T. <i>Clinical Cardiology</i> , 2015, 38, 230-235.	0.7	15
111	Serial Cardiac Troponin Measured Using a High-Sensitivity Assay in Stable Patients With Ischemic Heart Disease. <i>Journal of the American College of Cardiology</i> , 2016, 68, 322-323.	1.2	14
112	Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1288-1299.	2.2	14
113	Universal Classification System Type of Incident Myocardial Infarction in Patients With Stable Atherosclerosis: Observations From Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 ^Â P)-TIMI 50. <i>Journal of the American Heart Association</i> , 2016, 5,	1.6	13
114	Appropriate secondary prevention and clinical outcomes after acute myocardial infarction according to atherothrombotic risk stratification: The FAST-MI 2010 registry. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 411-419.	0.8	13
115	Contemporary Review of Antithrombotic Therapy in Peripheral Artery Disease. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e009584.	1.4	13
116	Exercise Training and Revascularization in the Management of Symptomatic Peripheral Artery Disease. <i>JACC Basic To Translational Science</i> , 2021, 6, 174-188.	1.9	13
117	Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER PAD trial. <i>European Heart Journal</i> , 2021, 42, 4040-4048.	1.0	13
118	Elevated concentration of placental growth factor (PIGF) and long term risk in patients with acute coronary syndrome in the PROVE IT-TIMI 22 trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2012, 34, 222-228.	1.0	12
119	Response by Bonaca and Sabatine to Letters Regarding Article, "Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With) Tj ETQq1 1 0.784314 r gBT /Ove	1.6	12
120	Sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: Barriers and solutions for improving uptake in routine clinical practice. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1187-1196.	2.2	12
121	Hemodynamic Significance of Periprocedural Myocardial Injury Assessed With N-Terminal Pro-B-Type Natriuretic Peptide After Percutaneous Coronary Intervention in Patients With Stable and Unstable Coronary Artery Disease (from the JUMBO-TIMI 26 Trial). <i>American Journal of Cardiology</i> , 2007, 99, 344-348.	0.7	11
122	Atherothrombotic risk stratification after acute myocardial infarction: the TIMI Risk Score for Secondary Prevention (TRS-2P) in the light of the FAST-MI registries. <i>Clinical Cardiology</i> , 2018, 42, 227-234.	0.7	11
123	Outcome associated with prescription of cardiac rehabilitation according to predicted risk after acute myocardial infarction: Insights from the FAST-MI registries. <i>Archives of Cardiovascular Diseases</i> , 2019, 112, 459-468.	0.7	11
124	Prognostic role of GDF-15 across the spectrum of clinical risk in patients with NSTEMI-ACS. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, 1084-1092.	1.4	11
125	Recombinant human lecithin-cholesterol acyltransferase in patients with atherosclerosis: phase 2a primary results and phase 2b design. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, ,	1.4	11
126	Rivaroxaban and Risk of Venous Thromboembolism in Patients With Symptomatic Peripheral Artery Disease After Lower Extremity Revascularization. <i>JAMA Network Open</i> , 2022, 5, e2215580.	2.8	11

#	ARTICLE	IF	CITATIONS
127	Diagnostic Performance of Copeptin in Patients With Acute Nontraumatic Chest Pain: <sc>BWHâ€™TIMI ED</sc> Chest Pain Study. <i>Clinical Cardiology</i> , 2014, 37, 227-232.	0.7	10
128	Antiplatelet Therapy for Long-term Secondary Prevention After Myocardial Infarction. <i>JAMA Cardiology</i> , 2016, 1, 627.	3.0	10
129	Sodium Glucose Cotransporter 2 Inhibitors and Amputation Risk. <i>Circulation</i> , 2018, 137, 1460-1462.	1.6	9
130	Acute Dissection of the Descending Aorta: A Case Report and Review of the Literature. <i>Cardiology and Therapy</i> , 2013, 2, 199-213.	1.1	8
131	TCT-78 Efficacy of Long-Term Ticagrelor in Stented Patients in PEGASUS-TIMI 54. <i>Journal of the American College of Cardiology</i> , 2015, 66, B36.	1.2	8
132	Vorapaxar in patients with coronary artery bypass grafting: Findings from the TRA 2Â°P-TIMI 50 trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017, 6, 164-172.	0.4	8
133	Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUSâ€™TIMI 54. <i>Journal of the American Heart Association</i> , 2018, 7, e009260.	1.6	8
134	Acute Aortic Syndromes. <i>Cardiology Clinics</i> , 2021, 39, 495-503.	0.9	8
135	Rationale and design of a study to assess the safety and efficacy of rNAPc2 in COVID-19: the Phase 2b ASPEN-COVID-19 trial. <i>American Heart Journal</i> , 2022, 246, 136-143.	1.2	8
136	Sexâ€™Based Differences in Outcomes Following Peripheral Artery Revascularization: Insights From VOYAGER PAD. <i>Journal of the American Heart Association</i> , 2022, 11, .	1.6	8
137	Time for a New Strategy for High-Sensitivity Troponin in the Emergency Department. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2237-2239.	1.2	7
138	Polyvascular disease and risk: When two is not better than one. <i>Vascular Medicine</i> , 2018, 23, 531-533.	0.8	7
139	Antithrombotic Therapy and Majorâ€™Adverse Limb Events in Peripheralâ€™Arteryâ€™Disease. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2316-2318.	1.2	7
140	Efficacy and safety of more potent antiplatelet therapy with vorapaxar in patients with impaired renal function. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 47, 353-360.	1.0	7
141	Caffeinated Beverage Intake, Dyspnea With Ticagrelor, and Cardiovascular Outcomes: Insights From the PEGASUSâ€™TIMI 54 Trial. <i>Journal of the American Heart Association</i> , 2020, 9, e015785.	1.6	7
142	Cardiovascular Biomarkers and Heart Failure Risk in Stable Patients With Atherothrombotic Disease: A Nested Biomarker Study From TRA 2Â°Pâ€™TIMI 50. <i>Journal of the American Heart Association</i> , 2021, 10, e018673.	1.6	7
143	Longâ€™Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUSâ€™TIMI 54 Trial. <i>Journal of the American Heart Association</i> , 2021, 10, e020446.	1.6	7
144	The conundrum of ALI and systemic embolic events: SEEing our way to improved vascular health. <i>Vascular Medicine</i> , 2016, 21, 535-538.	0.8	6

#	ARTICLE	IF	CITATIONS
145	Prasugrel Versus Ticagrelor. <i>Circulation</i> , 2016, 134, 1613-1616.	1.6	6
146	Inflammation begets inflammation: cancer and acute MI. <i>European Heart Journal</i> , 2020, 41, 2194-2196.	1.0	6
147	Genetic Risk Score to Identify Risk of Venous Thromboembolism in Patients With Cardiometabolic Disease. <i>Circulation Genomic and Precision Medicine</i> , 2021, 14, e003006.	1.6	6
148	Patterns of Long-Term Thienopyridine Therapy and Outcomes in Patients With Acute Coronary Syndrome Treated With Coronary Stenting: Observations From the <sc>TIMI</sc>â€”38 Coronary Stent Registry. <i>Clinical Cardiology</i> , 2014, 37, 293-299.	0.7	5
149	Outcomes in Stable Patients With Previous Atherothrombotic Events Receiving Vorapaxar Who Experience a New Acute Coronary Event (from TRA2Â°P-TIMI 50). <i>American Journal of Cardiology</i> , 2016, 117, 1055-1058.	0.7	5
150	How does the TRS 2Â°P score relate to real-world patients?. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 72-74.	1.4	5
151	ASCVD Risk and Statin Use in PAD. <i>Journal of the American College of Cardiology</i> , 2020, 76, 265-267.	1.2	5
152	No Significant Relationship Between Ticagrelor and Sleep Apnea in Large, Randomized, Blinded Trials. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 1012-1014.	1.1	5
153	Efficacy and safety of vorapaxar for secondary prevention in low body weight in patients with atherosclerosis: analyses from the TRA 2Â°P-TIMI 50 Trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 190-199.	0.4	5
154	Healthcare resource utilization and costs of major atherothrombotic vascular events among patients with peripheral artery disease after revascularization. <i>Journal of Medical Economics</i> , 2021, 24, 402-409.	1.0	5
155	Incidence of Major Atherothrombotic Vascular Events among Patients with Peripheral Artery Disease after Revascularization. <i>Annals of Vascular Surgery</i> , 2021, 75, 217-226.	0.4	5
156	Acute aortic syndromes: a review of what we know and future considerations. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 1197-1203.	0.4	5
157	Ischaemic and bleeding risk in atrial fibrillation with and without peripheral artery disease and efficacy and safety of full- and half-dose edoxaban vs. warfarin: insights from ENGAGE AF-TIMI 48. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 695-706.	1.4	5
158	Diabetes Mellitus and Risk Stratification After Peripheral Artery Revascularization. <i>Journal of the American College of Cardiology</i> , 2021, 77, 2867-2869.	1.2	4
159	At-home sample collection is an effective strategy for diagnosis and management of symptomatic and asymptomatic SARS-CoV-2 carriers. <i>BMC Infectious Diseases</i> , 2022, 22, 443.	1.3	4
160	Total Cardiovascular and Limb Events and the Impact of Polyvascular Disease in Chronic Symptomatic Peripheral Artery Disease. <i>Journal of the American Heart Association</i> , 2022, 11, .	1.6	4
161	Subclavian stenosis causing angina after coronary artery bypass grafting. <i>Medical Journal of Australia</i> , 2009, 190, 331-332.	0.8	3
162	Response to Letter Regarding Articles, â€œLong-Term Cardiovascular Mortality After Procedure-Related or Spontaneous Myocardial Infarction in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome: A Collaborative Analysis of Individual Patient Data From the FRISC II, ICTUS, and RITA-3 Trials (FIR)â€”and â€œAmerican College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation Universal Definition of Myocardial Infarction Classification System and the Risk of Cardi. <i>Circulation</i> , 2012, 126, .	1.6	3

#	ARTICLE	IF	CITATIONS
163	Ticagrelor for acute coronary syndromes. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 1473-1484.	0.6	3
164	Vorapaxar for secondary prevention in the elderly with peripheral artery disease: Insights from the TRA 2A ^o P-TIMI 50 trial. <i>Vascular Medicine</i> , 2019, 24, 159-161.	0.8	3
165	Antithrombotic strategies for patients with coronary and lower extremity peripheral artery diseases: a narrative review. <i>Expert Review of Cardiovascular Therapy</i> , 2020, 18, 881-889.	0.6	3
166	Extended dual antiplatelet therapy with ticagrelor 60 mg in patients with prior myocardial infarction: The design of ALETHEIA, a multi-country observational study. <i>Clinical Cardiology</i> , 2021, 44, 1333-1343.	0.7	3
167	Vorapaxar for Prevention of Major Adverse Cardiovascular and Limb Events in Peripheral Artery Disease. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2022, 27, 107424842110561.	1.0	3
168	Challenges of long-term dual antiplatelet therapy use following acute coronary syndromes. <i>American Heart Journal</i> , 2022, 246, 44-64.	1.2	3
169	Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: Dual anticoagulant/antiplatelet regimen vs antiplatelet therapy alone. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1193-1205.	1.9	3
170	Improvement in walking impairment following surgical and endovascular revascularization: Insights from VOYAGER PAD. <i>Vascular Medicine</i> , 2022, 27, 343-349.	0.8	3
171	Call for Formalized Pathways in Vascular Medicine Training. <i>Journal of the American College of Cardiology</i> , 2022, 79, 2129-2139.	1.2	3
172	Antithrombotics in Acute Coronary Syndromes: Updates from the Past Year. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2010, 12, 84-99.	0.4	2
173	Antiplatelet Therapy for Secondary Prevention After Acute Myocardial Infarction. <i>Interventional Cardiology Clinics</i> , 2017, 6, 119-129.	0.2	2
174	Pathology of Arterial Disease in Limb Loss. <i>Journal of the American College of Cardiology</i> , 2018, 72, 2164-2165.	1.2	2
175	DAPAGLIFLOZIN AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES AND PRIOR MYOCARDIAL INFARCTION: A SUB-ANALYSIS FROM DECLARE TIMI-58 TRIAL. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1.	1.2	2
176	New clues for optimal diagnosis and treatment of an old foe: the acute aortic syndrome. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020, 9, S1-S2.	0.4	2
177	Ankle-Brachial Index for Risk Stratification in Patients With Symptomatic Peripheral Artery Disease With and Without Prior Lower Extremity Revascularization: Observations From the EUCLID Trial. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e009871.	1.4	2
178	Rivaroxaban in Patients With Recent Peripheral Artery Revascularization and Renal Impairment. <i>Journal of the American College of Cardiology</i> , 2021, 78, 757-759.	1.2	2
179	Etiology and outcomes of amputation in patients with peripheral artery disease in the EUCLID trial. <i>Journal of Vascular Surgery</i> , 2022, 75, 660-670.e3.	0.6	2
180	Descending Aortic Dissection, Penetrating Aortic Ulcer, and Intramural Hematoma (Acute and)		

#	ARTICLE	IF	CITATIONS
181	Risk of remnants and remnant risk in peripheral artery disease. <i>European Heart Journal</i> , 2022, 43, 3270-3272.	1.0	2
182	Understanding Study Drug Discontinuation Through EUCLID. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	2
183	Glycoprotein IIb/IIIa Inhibitors in the Emergency Department for Patients with Non-ST-Elevation Acute Coronary Syndromes: Principles and Practices. <i>Journal of Emergency Medicine</i> , 2009, 36, 162-170.	0.3	1
184	Management of Asymptomatic Carotid Artery Stenosis. Current Treatment Options in <i>Cardiovascular Medicine</i> , 2013, 15, 252-263.	0.4	1
185	Editorial on PEGASUS-TIMI 54. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015, 1, 217-219.	1.4	1
186	Utility of multimodality imaging in myopericarditis with aortitis. <i>Journal of Nuclear Cardiology</i> , 2017, 24, 1103-1106.	1.4	1
187	Reply. <i>Journal of the American College of Cardiology</i> , 2018, 71, 108.	1.2	1
188	Heterogeneity of Risk and Benefit in Subgroups of COMPASS. <i>Journal of the American College of Cardiology</i> , 2019, 73, 3292-3294.	1.2	1
189	Tackling Elevated Risk in PAD: Focus on Antithrombotic and Lipid Therapy for PAD. <i>Current Cardiology Reports</i> , 2020, 22, 13.	1.3	1
190	Medical Therapy for Secondary Prevention of Atherothrombotic Events in Peripheral Artery Disease. <i>Heart International</i> , 2021, 15, 14.	0.4	1
191	Abstract 14170: Reduction in Venous Thromboembolism With Rivaroxaban versus Placebo in Peripheral Artery Disease After Lower Extremity Revascularization: Insights From VOYAGER PAD. <i>Circulation</i> , 2020, 142, .	1.6	1
192	Abstract 17116: Incidence and Costs of Major Atherothrombotic Vascular Events Among Patients With Peripheral Artery Disease After Revascularization. <i>Circulation</i> , 2020, 142, .	1.6	1
193	Efficacy and Safety of Vorapaxar by Intensity of Background Lipid-Lowering Therapy in Patients With Peripheral Artery Disease: Insights From the TRA2Pâ€¦TIMI 50 Trial. <i>Journal of the American Heart Association</i> , 2021, 10, e021412.	1.6	1
194	Impact of Polyvascular Disease and Diabetes on Limb and Cardiovascular Risk in Peripheral Artery Disease. <i>Journal of the American College of Cardiology</i> , 2022, 79, 1781-1783.	1.2	1
195	Left Ventricular Thrombosis Refractory to Medical Therapy. <i>Journal of the American College of Cardiology</i> , 2010, 56, e37.	1.2	0
196	PROGNOSTIC PERFORMANCE OF SERIAL HIGH SENSITIVITY CARDIAC TROPONIN DETERMINATION IN STABLE ISCHEMIC HEART DISEASE: ANALYSIS FROM PROVE IT-TIMI 22. <i>Journal of the American College of Cardiology</i> , 2013, 61, E1147.	1.2	0
197	Primary Stroke Prevention. <i>Interventional Cardiology Clinics</i> , 2014, 3, 1-11.	0.2	0
198	Antithrombotic Therapy in Patients With Peripheral Artery Disease. <i>JAMA Cardiology</i> , 2016, 1, 803.	3.0	0

#	ARTICLE	IF	CITATIONS
199	ACUTE AORTIC DISSECTION IN PATIENTS WITHOUT A HISTORY OF HYPERTENSION. Journal of the American College of Cardiology, 2017, 69, 2085.	1.2	0
200	RS13. Risk of Major Adverse Limb Events and Benefits of Evolocumab in Patients With Peripheral Artery Disease by History of Prior Peripheral Revascularization. Journal of Vascular Surgery, 2019, 69, e195.	0.6	0
201	RISK AND COSTS AFTER PERIPHERAL REVASCLARIZATION IN PATIENTS WITH PERIPHERAL ARTERY DISEASE WITH AND WITHOUT DIABETES. Journal of the American College of Cardiology, 2020, 75, 1303.	1.2	0
202	The Pathobiology of Acute Limb Ischemic Events and Stent Failure in Peripheral Artery Disease. JACC: Cardiovascular Interventions, 2020, 13, 428-430.	1.1	0
203	American Heart Association Vascular Disease Strategically Focused Research Network. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, e47-e54.	1.1	0
204	Reply to "The VOYAGER PAD Trial in Surgical Perspective: A Debate". European Journal of Vascular and Endovascular Surgery, 2021, 61, 723-724.	0.8	0
205	Novel views on finding an old foe: non-contrast computed tomography in the diagnosis of acute aortic syndromes. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 976-977.	0.4	0
206	Abstract 19720: Jay D. Coffman Early Career Investigator Award: Comparative Efficacy of Initial Endovascular Revascularization vs. Supervised Exercise Training in Patients With Intermittent Claudication: A Meta-analysis of Randomized Controlled Trials. Circulation, 2015, 132, .	1.6	0
207	Abstract 14141: A Contemporary Assessment of Lipid Lowering Therapies and Low-density Lipoprotein Cholesterol in Peripheral Artery Disease. Circulation, 2020, 142, .	1.6	0